Eterna Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
0.600
+0.131 (27.96%)
Jan 22, 2025, 2:19 PM EST - Market open
Eterna Therapeutics Revenue
Eterna Therapeutics had revenue of $487.00K in the quarter ending September 30, 2024, with 854.90% growth. This brings the company's revenue in the last twelve months to $598.00K, up 1,072.55% year-over-year. In the year 2023, Eterna Therapeutics had annual revenue of $68.00K.
Revenue (ttm)
$598.00K
Revenue Growth
+1,072.55%
P/S Ratio
4.24
Revenue / Employee
$74,750
Employees
8
Market Cap
30.82M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
ERNA News
- 8 days ago - Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer - GlobeNewsWire
- 13 days ago - Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors - GlobeNewsWire
- 2 months ago - Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing - GlobeNewsWire
- 3 months ago - Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success - GlobeNewsWire
- 3 months ago - Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - GlobeNewsWire
- 9 months ago - Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs - GlobeNewsWire
- 9 months ago - Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board - GlobeNewsWire
- 1 year ago - Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors - GlobeNewsWire